| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $826,067 ) |
| | 2025 | 2025 | ABZYME THERAPEUTICS LLC | 321 JONES BLVD | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R44EY030821 | Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | 000 | 3 | NIH | 3/31/2025 | $826,067 |
|
| Issue Date FY: 2024 ( Subtotal = $831,927 ) |
| | 2024 | 2024 | ABZYME THERAPEUTICS LLC | 321 JONES BLVD | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R44EY030821 | Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | 000 | 2 | NIH | 2/29/2024 | $831,927 |
| | 2024 | 2021 | ABZYME THERAPEUTICS LLC | 321 JONES BLVD | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43NS120624 | Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis | 000 | 1 | NIH | 4/15/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $299,999 ) |
| | 2023 | 2023 | ABZYME THERAPEUTICS LLC | 321 JONES BLVD | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43AI174703 | Novel immune-escape uricase for treatment of hyperuricemia | 000 | 1 | NIH | 5/22/2023 | $299,999 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2019 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43EY030821 | Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | 000 | 1 | NIH | 2/15/2022 | $0 |
| | 2022 | 2019 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43AI151635 | Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy | 000 | 1 | NIH | 4/6/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $399,107 ) |
| | 2021 | 2021 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43NS120624 | Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis | 000 | 1 | NIH | 9/10/2021 | $399,107 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43NS105172 | Modular antibody engineering to overcome the blood brain barrier | 001 | 1 | NIH | 2/16/2020 | $0 |
| | 2020 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R44GM106519 | High throughput camelid antibody screening as a drug discovery platform | 000 | 3 | NIH | 2/8/2020 | $0 |
| | 2020 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43GM122126 | Development Of Arginine Linkage-Specific Antibodies | 000 | 1 | NIH | 2/8/2020 | $0 |
| | 2020 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43NS105172 | Modular antibody engineering to overcome the blood brain barrier | 000 | 1 | NIH | 2/10/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $580,341 ) |
| | 2019 | 2019 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43EY030821 | Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases | 000 | 1 | NIH | 8/28/2019 | $299,989 |
| | 2019 | 2019 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43AI151635 | Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy | 000 | 1 | NIH | 8/13/2019 | $280,352 |
| | 2019 | 2016 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43DA042461 | Novel approach for rapid generation of human antibodies to RNA-modifications | 000 | 1 | NIH | 10/30/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $170,345 ) |
| | 2018 | 2018 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R44GM106519 | High throughput camelid antibody screening as a drug discovery platform | 000 | 3 | NIH | 8/23/2018 | $170,345 |
|
| Issue Date FY: 2017 ( Subtotal = $1,211,359 ) |
| | 2017 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43NS105172 | Modular antibody engineering to overcome the blood brain barrier | 000 | 1 | NIH | 9/22/2017 | $236,646 |
| | 2017 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43GM122126 | Development Of Arginine Linkage-Specific Antibodies | 000 | 1 | NIH | 9/14/2017 | $224,926 |
| | 2017 | 2017 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R44GM106519 | High throughput camelid antibody screening as a drug discovery platform | 000 | 3 | NIH | 8/23/2017 | $749,787 |
| | 2017 | 2016 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43CA193101 | Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation | 000 | 1 | NIH | 3/1/2017 | $0 |
| | 2017 | 2015 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43EY025123 | Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis | 000 | 1 | NIH | 4/5/2017 | $0 |
| | 2017 | 2015 | ABZYME THERAPEUTICS, LLC | 321 JONES BLVD, STE 300 | POTTSTOWN | PA | 19464-3468 | MONTGOMERY | USA | R43GM115011 | High throughput approach for generating human monoclonal antibodies | 000 | 1 | NIH | 9/22/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $1,014,817 ) |
| | 2016 | 2016 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R44GM106519 | High throughput camelid antibody screening as a drug discovery platform | 000 | 2 | NIH | 8/24/2016 | $750,213 |
| | 2016 | 2016 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43CA193101 | Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation | 000 | 1 | NIH | 3/9/2016 | $39,966 |
| | 2016 | 2016 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43DA042461 | Novel approach for rapid generation of human antibodies to RNA-modifications | 000 | 1 | NIH | 6/17/2016 | $224,638 |
|
| Issue Date FY: 2015 ( Subtotal = $674,515 ) |
| | 2015 | 2015 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43GM115011 | High throughput approach for generating human monoclonal antibodies | 000 | 1 | NIH | 6/22/2015 | $224,799 |
| | 2015 | 2015 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43EY025123 | Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis | 000 | 1 | NIH | 2/3/2015 | $224,935 |
| | 2015 | 2015 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43CA193101 | Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation | 000 | 1 | NIH | 4/30/2015 | $224,781 |
|
| Issue Date FY: 2014 ( Subtotal = $667,909 ) |
| | 2014 | 2014 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43DA038980 | Nanobodies for detecting and manipulating A to I editing enzymes and their modified RNA products | 000 | 1 | NIH | 8/18/2014 | $224,975 |
| | 2014 | 2014 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43AI114214 | Novel bispecific T cell engaging antibodies for treatment of Lyme disease | 000 | 1 | NIH | 8/15/2014 | $224,849 |
| | 2014 | 2014 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43GM106519 | High throughput camelid antibody screening as drug discovery platform | 001 | 1 | NIH | 5/9/2014 | $18,437 |
| | 2014 | 2014 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43GM106519 | High throughput camelid antibody screening as drug discovery platform | 000 | 1 | NIH | 4/10/2014 | $199,648 |
|
| Issue Date FY: 2011 ( Subtotal = $282,519 ) |
| | 2011 | 2011 | ABZYME THERAPEUTICS LLC | 271 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | CHESTER | USA | R43AG039892 | HUMAN PROTEOLYTIC BETA-AMYLOID SPECIFIC ANTIBODIES FOR TREATMENT OF ALZHEIMERS DI | 000 | 1 | NIH | 6/13/2011 | $282,519 |
|
|
